The increasing incidence of atopic dermatitis (AD) and poor recognition of the disease in
some patient groups is a public health concern. AD symptoms and its daily management
cause significant effects on quality of life for both patients and caregivers. Timely and
adequate treatment of AD is essential for helping to promote better long-term
outcomes and quality of life and may help prevent the development of other atopic
conditions. However, the treatment of AD is a clinical challenge. Although in many
patients AD symptoms can be controlled primarily with topical agents, long-term
treatment can be challenging or may not be adequately addressed. Targeted
immunomodulatory agents, based on recent advances in the understanding of AD
pathophysiology, represent additional options for long-term control. In particular, Janus
kinase (JAK) inhibitors have emerged as a novel mechanism of action for treatment of
AD with one agent that is FDA approved and several others in advanced clinical
development. Thus, additional education about current and emerging long-term
strategies to AD management is crucial for their interpretation and application to clinical practice.
This educational activity is designed to provide guidance to clinicians who are in need
of additional training to understand these new mechanisms of action and appropriate
prescribing methods for emerging immunomodulatory therapies. Clinicians will be
more knowledgeable and competent regarding the efficacy and safety of current and
emerging agents, including any potential adverse effects, such as altered
immunocompetence, as well as strategies for implementation into their practice.
Interpret the efficacy and safety of current non-pharmacological and pharmacological treatments for AD and their limitations in long-term disease management.
Summarize the mechanisms of action and evidence with new and emerging targeted immunomodulatory agents for long-term AD management.
Develop individualized treatment plans for patients with moderate-to-severe AD that go beyond just treating flares and symptoms in order to optimize long-term control and overall quality of life.
Apply best practices for vaccination of immunocompromised AD patients.
Live Webinar Agenda
|7:00 pm - 7:05 pm||Introduction: Review of Primer-Melinda Gooderham, MD|
-Brief overview of AD pathophysiology, diagnosis, and current pharmacologic and non-pharmacologic interventions
|7:05 pm - 7:20 pm||Emerging Biologics for AD-Melinda Gooderham, MD|
-Review existing biologics used for treatment of AD
-Interpret latest clinical trial data for biologics currently in development
|7:20 pm - 7:40 pm||JAK Inhibitors in Atopic Dermatitis-Brett King, MD|
-Review JAK-STAT pathway and its role in AD pathophysiology
-Mechanism of action video
-Discuss emerging JAK inhibitors being developed for treatment of AD
-Review latest clinical trial data including safety and efficacy
|7:40 pm 7:55 pm||Altered Immunocompetence and Vaccination in AD Patients-Kim Papp, MD|
-Discuss immunosuppressive agents used for treatment of AD and their effects on patients’ immunocompetence
-Review guidelines and recommendations for vaccination of patients with altered immunocompetence
|7:55 pm - 8:00 pm||Conclusion/Q&A-All Faculty|
Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and LiVDerm
This activity is supported by educational grants from Incyte Corporation and Pfizer Inc.
This activity is designed for an audience of U.S. based dermatologists and allergists, physician assistants, pharmacists and nurses who are in the care and treatment of patients with moderate-to-severe atopic dermatitis.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistant Continuing Medical Education
AKH In., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.
Credit being awarded: 1.0 ANCC contact hours
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.0 contact hours.
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CE activity, please contact AKH Inc. at email@example.com. There is no fee for this activity.